There are currently 1258 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Recruiting
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Atherosclerotic Cardiovascular Disease
PRO1107 in Patients With Advanced Solid Tumors
Recruiting
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Recruiting
This prospective randomized clinical trial will compare outcomes between patients treated primarily with a prophylactic antibiotic coated nail and those treated with traditional standard of care intramedullary (IM) nailing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Osteomyelitis Tibia, Tibial Fractures, Open tíbia Fracture
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Recruiting
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)? * What medical problems do participants have when taking ARD-101? Researchers will compare ARD-101 to a placebo (a look-alike substance that con... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Hyperphagia, Prader-Willi Syndrome
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Recruiting
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt Eye Institute, Nashville, Tennessee
Conditions: Retinitis Pigmentosa
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Research Site, Nashville, Tennessee +1 locations
Conditions: Breast Cancer
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Recruiting
IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Tennessee Oncology Nashville /ID# 269029, Nashville, Tennessee
Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Recruiting
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
06/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Progressive Supranuclear Palsy
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Post-Bariatric Hypoglycemia
Primary Subtalar Arthrodesis for Calcaneal Fractures
Recruiting
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Calcaneus Fracture
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Recruiting
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration will be up to approximately 11 months. * The treatment duration will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug;... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma